[{"innerBlocks":[],"name":"core\/freeform","postId":637,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"The Centers for Medicare and Medicaid Services has finalized a rule<\/a> to promote quicker access to new medical technology through changes in payment policies.\u201cPresident Trump is strengthening Medicare by clearing the way for Medicare beneficiaries to access the same transformative technologies and treatment options emerging in the private market,\u201d said CMS Administrator Seema Verma in a written statement.

\u201cThrough our efforts to improve transparency and reduce regulatory burden, we are hearing more than ever from innovators who want to work with us so that Medicare beneficiaries have access to the latest advances in healthcare,\u201d Verma added.Also See<\/b>: CMS issues final rule to provide patients with access to health data<\/a>The Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital Prospective Payment System for Fiscal Year 2020 increases Medicare add-on payments\u2014called new technology add-on payments (NTAP)\u2014for cases with high costs involving eligible new technologies, with payment increasing from 50 percent to 65 percent.\u201cUnder the current new technology add-on payment calculation, Medicare pays a marginal cost factor of 50 percent of the estimated costs of the case in excess of the full (Diagnosis-Related Group) payment, up to a maximum of 50 percent of the costs of the technology,\u201d according to the agency. \u201cCMS believes that setting the maximum add-on payment percentage at 50 percent may not result in an appropriate add-on payment. To address this issue, CMS is finalizing an increase to the add-on payment, beginning in FY 2020, from 50 percent to 65 percent, and additionally is increasing the add-on payment to 75 percent for certain antimicrobials.\u201dIn addition, CMS is revising payment policies for medical devices that meet the Food and Drug Administration\u2019s Breakthrough Devices designation for expedited FDA approval or clearance.The FDA\u2019s Breakthrough Devices Program\u2014first authorized in late 2016\u2014is intended to offer new ways to treat or diagnose a disease or condition, have significant advantages over existing treatment or diagnostic alternatives or provide another public health benefit. \u201cCMS finalized an alternative NTAP pathway in which breakthrough devices would no longer be required to demonstrate evidence of \u2018substantial clinical improvement\u2019 to qualify for new technology add-on payments,\u201d states the agency\u2019s announcement. \u201cThis will provide additional Medicare payment for these technologies while real-world evidence is emerging, giving Medicare beneficiaries timely access to the latest innovations in treatment.\u201d","saveContent":"The Centers for Medicare and Medicaid Services has finalized a rule<\/a> to promote quicker access to new medical technology through changes in payment policies.\u201cPresident Trump is strengthening Medicare by clearing the way for Medicare beneficiaries to access the same transformative technologies and treatment options emerging in the private market,\u201d said CMS Administrator Seema Verma in a written statement. \u201cThrough our efforts to improve transparency and reduce regulatory burden, we are hearing more than ever from innovators who want to work with us so that Medicare beneficiaries have access to the latest advances in healthcare,\u201d Verma added.Also See<\/b>: CMS issues final rule to provide patients with access to health data<\/a>The Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital Prospective Payment System for Fiscal Year 2020 increases Medicare add-on payments\u2014called new technology add-on payments (NTAP)\u2014for cases with high costs involving eligible new technologies, with payment increasing from 50 percent to 65 percent.\u201cUnder the current new technology add-on payment calculation, Medicare pays a marginal cost factor of 50 percent of the estimated costs of the case in excess of the full (Diagnosis-Related Group) payment, up to a maximum of 50 percent of the costs of the technology,\u201d according to the agency. \u201cCMS believes that setting the maximum add-on payment percentage at 50 percent may not result in an appropriate add-on payment. To address this issue, CMS is finalizing an increase to the add-on payment, beginning in FY 2020, from 50 percent to 65 percent, and additionally is increasing the add-on payment to 75 percent for certain antimicrobials.\u201dIn addition, CMS is revising payment policies for medical devices that meet the Food and Drug Administration\u2019s Breakthrough Devices designation for expedited FDA approval or clearance.The FDA\u2019s Breakthrough Devices Program\u2014first authorized in late 2016\u2014is intended to offer new ways to treat or diagnose a disease or condition, have significant advantages over existing treatment or diagnostic alternatives or provide another public health benefit. \u201cCMS finalized an alternative NTAP pathway in which breakthrough devices would no longer be required to demonstrate evidence of \u2018substantial clinical improvement\u2019 to qualify for new technology add-on payments,\u201d states the agency\u2019s announcement. \u201cThis will provide additional Medicare payment for these technologies while real-world evidence is emerging, giving Medicare beneficiaries timely access to the latest innovations in treatment.\u201d","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

CMS final rule seeks to unleash medical innovation

More for you